Sun Pharma to acquire US-based Concert for $576 million

Concert's lead candidate, deuruxolitinib, is being evaluated as a treatment for autoimmune condition alopecia areata, which results in patchy hair loss.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news